Momelotinib for myelofibrosis: our 14 years of experience with 100 clinical trial patients and recent FDA approval by Ayalew Tefferi, Animesh Pardanani

Get full text

Prognostic relevance of anemia and transfusion dependency in myelodysplastic syndromes and primary myelofibrosis by Animesh Pardanani, Ayalew Tefferi

Get full text

Momelotinib (JAK1/JAK2/ACVR1 inhibitor): mechanism of action, clinical trial reports, and therapeutic prospects beyond myelofibrosis by Ayalew Tefferi, Animesh Pardanani, Naseema Gangat

Get full text

How we diagnose and treat WHO-defined systemic mastocytosis in adults by Ayalew Tefferi, Srdan Verstovsek, Animesh Pardanani

Get full text

Thrombosis in myelofibrosis: prior thrombosis is the only predictive factor and most venous events are provoked by Michelle Ann Elliott, Animesh Pardanani, Terra L. Lasho, Susan M. Schwager, Ayalew Tefferi

Get full text

Determinants of survival and retrospective comparisons of 183 clinical trial patients with myelofibrosis treated with momelotinib, ruxolitinib, fedratinib or BMS- 911543 JAK2 inhib... by Naseema Gangat, Kebede H. Begna, Aref Al-Kali, William Hogan, Mark Litzow, Animesh Pardanani, Ayalew Tefferi

Get full text

Chronic Eosinophilic Leukemia—Not Otherwise Specified (NOS) in the Background of a Large Cell Lymphoma by Wilson I. Gonsalves, Rong He, Animesh Pardanani, Vinay Gupta, Jacob P. Smeltzer, Curtis A. Hanson, Thomas E. Witzig

Get full text

Targeted deep sequencing in primary myelofibrosis by Ayalew Tefferi, Terra L. Lasho, Christy M. Finke, Yoseph Elala, Curtis A. Hanson, Rhett P. Ketterling, Naseema Gangat, Animesh Pardanani

Get full text

CPX-351 (Vyxeos™) treatment in blast-phase myeloproliferative neoplasm (MPN-BP): real-world experience in 12 consecutive cases by Rimal Ilyas, Kristen McCullough, Talha Badar, Mrinal M. Patnaik, Hassan Alkhateeb, Abhishek Mangaonkar, Animesh Pardanani, Ayalew Tefferi, Naseema Gangat

Get full text

Erythrocytosis associated with <i>EPAS1</i>(<i>HIF2A</i>), <i>EGLN1</i>(<i>PHD2</i>), <i>VHL, EPOR</i> or <i>BPGM</i> mutations: The Mayo Clinic experience by Naseema Gangat, Jennifer L. Oliveira, Tavanna R Porter, James D. Hoyer, Aref Al-Kali, Mrinal M. Patnaik, Animesh Pardanani, Ayalew Tefferi

Get full text

Calr type 1/like mutation in myelofibrosis is the most prominent predictor of momelotinib drug survival and longevity without transplant by Ayalew Tefferi, Animesh Pardanani, Kebede H. Begna, Aref Al-Kali, William J. Hogan, Mark R. Litzow, Rhett P. Ketterling, Kaaren K. Reichard, Naseema Gangat

Get full text

Myeloid neoplasms with PHF6 mutations: context-dependent genomic and prognostic characterization in 176 informative cases by Saubia Fathima, Ali Alsugair, Rong He, Abhishek A. Mangaonkar, Kebede H. Begna, Animesh Pardanani, Cinthya J. Zepeda Mendoza, Kaaren K. Reichard, Naseema Gangat, Ayalew Tefferi

Get full text

Clinical correlates, prognostic impact and survival outcomes in chronic myelomonocytic leukemia patients with the JAK2V617F mutation by Mrinal M. Patnaik, Prateek A. Pophali, Terra L. Lasho, Christy M. Finke, Pedro Horna, Rhett P. Ketterling, Naseema Gangat, Abhishek A. Mangaonkar, Animesh Pardanani, Ayalew Tefferi

Get full text

One thousand patients with essential thrombocythemia: the Mayo Clinic experience by Naseema Gangat, Omer Karrar, Aref Al-Kali, Kebede H. Begna, Michelle A. Elliott, Alexandra P. Wolanskyj-Spinner, Animesh Pardanani, Curtis A. Hanson, Rhett P. Ketterling, Ayalew Tefferi

Get full text

The Ph-positive and Ph-negative myeloproliferative neoplasms: some topical pre-clinical and clinical issues by Richard A. Van Etten, Steffen Koschmieder, Francois Delhommeau, Danilo Perrotti, Tessa Holyoake, Animesh Pardanani, Ruben Mesa, Tony Green, Amr R. Ibrahim, Tariq Mughal, Robert Peter Gale, John Goldman

Get full text

Targeted next-generation sequencing in blast phase myeloproliferative neoplasms by Terra L. Lasho, Mythri Mudireddy, Christy M. Finke, Curtis A. Hanson, Rhett P. Ketterling, Natasha Szuber, Kebede H. Begna, Mrinal M. Patnaik, Naseema Gangat, Animesh Pardanani, Ayalew Tefferi

Get full text

Chronic phase CML with sole P190 (e1a2) BCR::ABL1: long-term outcome among ten consecutive cases by Maymona G. Abdelmagid, Mark R. Litzow, Kristen B. McCullough, Naseema Gangat, Animesh Pardanani, Hemant S. Murthy, James M. Foran, Rhett P. Ketterling, David Viswanatha, Kebede H. Begna, Ayalew Tefferi

Get full text

Molecular predictors of response to venetoclax plus hypomethylating agent in treatment-naïve acute myeloid leukemia by Naseema Gangat, Isla Johnson, Kristen McCullough, Faiqa Farrukh, Aref Al-Kali, Hassan Alkhateeb, Kebede Begna, Abhishek Mangaonkar, Mark Litzow, William Hogan, Mithun Shah, Mrinal Patnaik, Animesh Pardanani, Ayalew Tefferi

Get full text

Current pre-clinical and clinical advances in the BCR-ABL1-positive and -negative chronic myeloproliferative neoplasms by Tariq I. Mughal, Alessandro M. Vannucchi, Simona Soverini, Alexandra Bazeos, Raoul Tibes, Giuseppe Saglio, Omar Abdel-Wahab, Animesh Pardanani, Rudiger Hehlmann, Tiziano Barbui, Richard Van Etten, Ayalew Tefferi, John M. Goldman

Get full text

Outcome of patients with acute myeloid leukemia following failure of frontline venetoclax plus hypomethylating agent therapy by Naseema Gangat, Rimal Ilyas, Isla M Johnson, Kristen McCullough, Aref Al-Kali, Hassan B Alkhateeb, Kebede H Begna, Abhishek Mangaonkar, Mark R Litzow, William Hogan, Mithun Shah, Mrinal M Patnaik, Animesh Pardanani, Ayalew Tefferi

Get full text